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Introduction: Frequency of mutations in EGFR and KRAS in non-
small cell lung cancer (NSCLC) is different between ethnic groups;
however, there is no information in Latin-American population.
Methods: A total of 1150 biopsies of NSCLC patients from Latin
America (Argentina, Colombia, Peru, and Mexico) were used ex-
tracting genomic DNA to perform direct sequencing of EGFR gene
(exons 18 and 21) and KRAS gene in 650 samples. In Mexico,
Scorpions ARMS was also used to obtain a genetic profile.
Results: We report the frequency of mutations in EGFR and KRAS
genes in four Latin-American countries (n  1150). Frequency of
EGFR mutations in NSCLC was 33.2% (95% confidence interval
[CI] 30.5–35.9) (Argentina 19.3%, Colombia 24.8%, Mexico
31.2%, and Peru 67%). The frequency of KRAS mutations was
16.6% (95% CI 13.8–19.4). EGFR mutations were independently
associated with adenocarcinoma histology, older age, nonsmokers,
and absence of KRAS mutations. Overall response rate to tyrosine
kinase inhibitors in EGFR-mutated patients (n  56) was 62.5%
(95% CI 50–75) with a median overall survival of 16.5 months
(95% CI 12.4–20.6).
Conclusions: Our findings suggest that the frequency of EGFR
mutations in Latin America lies between that of Asian and Cauca-
sian populations and therefore support the genetic heterogeneity of
NSCLC around the world.
Key Words: Non-small cell lung cancer, Mutation, EGFR, KRAS,
Latin America.
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Subdividing non-small cell lung cancer (NSCLC) based onclinically relevant molecular alterations is a promising treat-
ment strategy. The most commonly mutated genes in lung
adenocarcinoma are KRAS and EGFR. Almost 90% of specific
EGFR mutations for lung cancer comprise the leucine-to-argin-
ine substitution at position 858 (L858R) and deletions in exon 19
that affect the conserved sequence LREA (delE746-A750).1
Those mutations cause constitutive activation of the tyrosine
kinase domain of the EGFR. Female patients, Asian ethnicity,
nonsmokers, and those with adenocarcinoma have higher fre-
quency of EGFR mutations.2 KRAS mutation usually occurs at
codon 12 (characterized by G-to-T transversions), occasionally
at codon 13, and rarely at codon 61, which sustains the activation
of the RAS signaling pathway.3
Activating EGFR mutations confer a special sensi-
tivity to the tyrosine kinase inhibitors gefitinib and erlo-
tinib,2 but patients with KRAS mutations have a lower
survival and response rate.4 It is known that NSCLC
patients harboring EGFR-dependent primary tumors can
develop resistance because of new kind of mutations such
as T790M for EGFR or cMET amplification.3
It has been shown that the frequency of mutations
varies between ethnic groups; EGFR mutations: 15% of
North American and European patients, 40% of Asian
patients, and between 2% and 14% of Afro-American
patients.5–8 Frequency of KRAS mutation is around 30%
in Caucasian population and 10% in East Asian subjects
with lung adenocarcinoma.9,10
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The precise frequency of activating mutations in the
Latin-American population has not been determined. Our
group previously reported a high response rate (34%) in
nonselected Mexican patients who progressed after chemo-
therapy, suggesting a higher frequency of EGFR mutations
among Hispanics.
PATIENTS AND METHODS
Patient Selection
A large cohort of Latin American patients with histo-
logically confirmed NSCLC (244 from Argentina, 322 from
Colombia, 381 from Mexico, and 203 from Peru) were
included; all gave their informed consent for testing, and the
protocol was approved by local Institutional Review Boards.
Tissue Attainment
Biopsies were taken using computed tomography-
guided tru-cut or by bronchoscopy and were analyzed by the
pathology departments of the different participating institu-
tions for their histological diagnosis and quantification of
neoplastic cellularity (50%). Thereafter the tumor tissue
was embebed in paraffin until DNA extraction.
DNA Extraction
Genomic DNA was extracted by a standard procedure
from areas of paraffin slides using the QIAamp DNAFFPE
Tissue Kit (QIAGEN) according to the manufacturer’s
instructions.
Mutational Analysis
Direct sequencing in patients from Argentina, Colom-
bia, Mexico, and Peru was performed at each site. The kinase
domain of the EGFR was amplified by polymerase chain
reaction (PCR). Two separate PCRs, each with the corre-
sponding pair of primers, were used to amplify the exons 19
and 21 of the EGFR genes. The codons 12 and 13 of the
KRAS were amplified by PCR with specific primers. These
PCR products were then subjected to direct sequencing using
the same primers, and all mutations were confirmed by
sequences originating from both the upstream and down-
stream primers. In Mexico, some mutations of EGFR (exons
18, 19, 20, and 21) and KRAS genes were detected by
Therascreen RGQ PCR Kit (QIAGEN, Scorpions ARMS
method), which combines two technologies, namely ARMS
and Scorpions, to detect mutations using real-time PCRs,
which was performed using a Rotor-Gene Q 5plex HRM
(QIAGEN), according to the manufacturer’s instructions.
Statistical Analysis
For descriptive purposes, continuous variables were
summarized as arithmetic means, medians, SDs, and categor-
ical variables comprised proportions with 95% confidence
intervals (95% CI). Inferential comparisons were carried out
by Student’s t test or Mann-Whitney U test according to the
distribution of the data (normal and non-normal) determined
by the Kolmogorov-Smirnov test. 2 or Fisher’s exact test
was used to assess significance among categorical variables.
Statistical significance was determined as p  0.05 with a
two-sided test. Statistically significant and borderline signif-
icant variables (p  0.1) were included in multivariate logis-
tic regression analysis. Progression-free survival was mea-
sured from day of starting treatment to the date of last
follow-up visit and analyzed using Kaplan-Meier technique,
whereas comparisons among subgroups were carried out with
the log-rank test. For analysis of survival curves, all variables
were dichotomized.
RESULTS AND DISCUSSION
Herein, we report the frequency of mutations in EGFR
and KRAS among Latin American countries including Ar-
gentina, Colombia, Mexico, and Peru. We included 1150
patients. Table 1 shows the clinical and pathological charac-
teristics of the population. We found activating mutations in
the EGFR gene in 382 of 1150 patients (33.2% [95% CI
30.5–35.9]). Our findings suggest that the frequency of EGFR
mutations in Latin America is between that of Asian (40%)
and European (15%) populations5–7 and support the existence
of ethnic variations in the frequency of these genomic alter-
ations.
In our study, 48.4% patients had exon 19 deletion
(DelEx19) and 49% have L858R mutation (Ex21) (Table 1).
These mutations account roughly for 90% of activating
EGFR mutations in NSCLC. These findings are consistent
with the data from Asian (DelEx19 60% and Ex21 40%) and
European populations (DelEx19 62.2% and Ex21 37.8%).6
Interestingly, we detected a high frequency of EGFR muta-
tions in patients from Peru (67%) as compared with other
countries from the region, probably due to the Asian migra-
tion and aborigine predominance. It is important to highlight
that in Peru, the relationship between DelEx19 and L858R is
inverted, meaning that it is different to the other studied
countries. Mexico had the second highest frequency of EGFR
mutations (31.2%); data are consistent with already published
response rate to erlotinib (34%) in nonselected lung cancer
patients.11
The EGFR mutations show an independent association
with adenocarcinoma histology (p  0.001), older patients
(p  0.002), and nonsmokers (p  0.001) (Table 2). These
results are similar to previous reports and confirm the pres-
ence of a different biological pattern, opposite to that de-
scribed for lung cancer induced by tobacco exposure.12 The
high frequency of EGFR mutations could be explained not
only by ethnicity but also by the high frequency of women
and nonsmokers, features suggesting a selection bias. How-
ever, smokers and men also display a higher frequency of
EGFR mutations compared with previous non-Latin-American
reports (24.6% and 29.5%, respectively) (Table 2). Our study
shows similar results than a previous report showing that EGFR
mutations were more frequent in older patients (69% in 57
years) than in the younger ones (39% in 57 years).13
Frequency of KRAS mutations at codons 12 and 13 was
16.6% (95% CI 13.8–19.4) among the 650 analyzed speci-
mens (Table 1), similar data to that reported in Asian popu-
lation.9,10 We found higher frequency of EGFR mutations in
patients without KRAS mutation (43.4% versus 4.6%, p 
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0.001). Although most reports indicate that EGFR and KRAS
mutations are mutually exclusive, suggesting the presence of
different pathways of lung carcinogenesis, our findings show
that KRAS mutation may coexist with EGFR mutation (4.6%),
similar to a previous report.14 We also found a higher frequency
of KRASmutations in smokers than in nonsmokers (20% versus
13.4%, p  0.029) as reported previously.15
Information about treatment outcomes could be ob-
tained from 56 EGFR-mutated patients treated in Mexico and
Colombia; all received a reversible tyrosine kinase inhibitor
in as first, second, third, and fourth lines in 26.7%, 35.7%,
26.8%, and 10.7%, respectively. We found a complete re-
sponse rate in 7.1%, partial response rate in 55.4% (overall
response rate 62.5%), and stable disease in 37.5%. Progres-
sion-free survival and overall survival were 15.1 (95% CI
12.4–17.9) and 16.4 months (12.4–20.6), respectively. No dif-
ference was found on overall survival between patients harbor-
ing DelEx19 (16.5 months [10.4–22.7]) or L858R (16.0 months
[11.1–20.9]; p  0.612); similar results were reported for pa-
tients treated with gefitinib as first-line therapy in patients with
EGFR mutations (Supplemental Figure 1, Supplemental Digital
Content 1, http://links.lww.com/JTO/A145).16
In conclusion, our findings suggest that the frequency
of EGFR mutations in Latin America lies between that of
Asian and Caucasian populations and complement growing
evidence pointing to genetic heterogeneity of EGFR pathway
in NSCLC among different ethnic groups. The increase in
frequency of EGFR mutations in Asian and Latin American
lung cancer patients compared with Caucasian ones could be
explained by a common origin but may also suggest a
possible genetic susceptibility to carcinogens present among
these populations. Other factors such as wood smoke expo-
sure and tuberculosis could be involved.11 Our results confirm
the need to consider ethnicity and geographical differences in
designing future clinical trials.
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TABLE 1. Patient Characteristics
Variable Argentina Colombia Mexico Peru Total
No. of patients 244 322 381 203 1150
Mean age  SD 61.3  10.1 58.8  12.8 59.8  13.2 62.8  10.9 60.3  12.2
Gender, n (%)
Female 140 (57.4) 216 (67.1) 215 (56.2) 99 (48.8) 670 (58.4)
Male 104 (42.6) 106 (32.9) 164 (43.3) 104 (51.2) 478 (41.6)
Histology, n (%)
Adenocarcinoma 244 (100) 263 (81.7) 300 (79.6) 203 (100) 1010 (90.4)
LCC 6 (2.0) 3 (0.8) 9 (0.8)
NOS/nondifferentiated 16 (5.5) 14 (3.7) 30 (2.7)
SCC 8 (2.7) 60 (15.9) 68 (6.1)
Smoking status, n (%)
Smoker 84 (41.4) 72 (27) 188 (49.7) 69 (34) 448 (42.6)
Never-smoker 119 (58.8) 195 (73) 190 (50.3) 134 (66) 603 (57.4)
Ethnicity, n (%)
Caucasian 243 (100) 51 (37) 6 (1.6) 6 (3) 306 (31.7)
Mestizo/indigenous 86 (62.3) 375 (98.4) 197 (97) 658 (68.2)
Black 1 (0.7) 0 0 1 (.1)
EGFR sensitizing mutation status, n (%)
Positive 47 (19.3) 80 (24.8) 119 (31.2) 136 (67) 382 (33.2)
Negative 197 (80.7) 242 (75.2) 262 (68.8) 67 (33) 768 (66.8)
Exon 18 () 1 (2.1) 11 (9.2) 12 (3.1)
Exon 19 deletion () 30 (63.8) 54 (67.5) 76 (63.9) 25 (18.4) 185 (48.4)
Exon 21 L858R () 19 (40.4) 26 (32.5) 31 (26) 111 (81.6) 187 (48.9)
Exon 20 S768I () 2 (4.2) 10 (8.4) 12 (3.1)
Complex mutations 2 (4.2) 0 11 (9.2) 0 13 (3.4)
T790M basal, n (%)
Positive 2 (0.8) 6 (5.2) 8 (2.1) 16 (2.2)
Negative 242 (99.2) 108 (94.7) 373 (97.9) 723 (97.8)
KRAS, n (%)
Positive 35 (17.1) 39 (16) 34 (16.8) 108 (16.6)
Negative 170 (82.9) 204 (84) 168 (83.2) 542 (83.4)
LCC, Large cell carcinoma; NOS, non small; SCC, squamous cell carcinoma.
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